Biomarkers with potential impact on outcome in patients treated for Hodgkin lymphoma
| Factor . | Impact on prognosis . | Reference . |
|---|---|---|
| Assessment of Hodgkin Reed-Sternberg cells | ||
| Aberrant T-cell antigen expression* | Negative | 61 |
| FOXP3 expression* | Negative | 66 |
| CD20 expression* | Negative | 66 |
| BCL-XL* | Negative | 77 |
| p53* | Negative | 77 |
| HLA class II, loss* | Negative | 75 |
| Presence of Epstein-Barr virus | Negative | 82-86 |
| Assessment of microenvironmental or circulating nonneoplastic cells, cytokines, and membrane-associated antigens | ||
| Fibroblast growth factor 2† | Negative | 67 |
| Syndecan-1† | Negative | 67 |
| Tumor-associated macrophages‡ | Negative | 68, 70,72, 87, 88 |
| CD68 expression‡ | Negative | 66 |
| Serum TARC, elevated | Negative | 63, 65 |
| Serum galectin-1, elevated | Negative | 64, 79 |
| Serum CD163, elevated | Negative | 65 |
| Serum IL-10, elevated | Negative | 73, 76, 78 |
| Serum IL-10 receptor, elevated | Negative | 76 |
| Serum IL-6, elevated | Negative | 76 |
| Serum CD30, elevated | Negative | 76, 78 |
| Serum TNF, elevated | Negative | 76 |
| Serum TNF receptor, elevated | Negative | 76 |
| Serum CD4, elevated | Negative | 78 |
| Serum CD8, elevated | Negative | 78 |
| Serum CD25, elevated | Negative | 78 |
| Serum CD54, elevated | Negative | 78 |
| Gene expression and miRNA profiling reflecting the tumor microenvironment | ||
| Gene expression profiling | Positive or negative | 62, 69 |
| Global miRNA levels, including MIR21, MIR30E, MIR30D, and MIR92B | Positive or negative | 80, 81 |
| Host germline polymorphisms and mutations | ||
| IL-10-specific polymorphism 592AA | Negative | 74 |
| IL-6-specific polymorphism 174GG | Negative | 74 |
| Germline NPAT mutation | Marker for risk of nodular lymphocyte–predominant Hodgkin lymphoma | 71 |
| Factor . | Impact on prognosis . | Reference . |
|---|---|---|
| Assessment of Hodgkin Reed-Sternberg cells | ||
| Aberrant T-cell antigen expression* | Negative | 61 |
| FOXP3 expression* | Negative | 66 |
| CD20 expression* | Negative | 66 |
| BCL-XL* | Negative | 77 |
| p53* | Negative | 77 |
| HLA class II, loss* | Negative | 75 |
| Presence of Epstein-Barr virus | Negative | 82-86 |
| Assessment of microenvironmental or circulating nonneoplastic cells, cytokines, and membrane-associated antigens | ||
| Fibroblast growth factor 2† | Negative | 67 |
| Syndecan-1† | Negative | 67 |
| Tumor-associated macrophages‡ | Negative | 68, 70,72, 87, 88 |
| CD68 expression‡ | Negative | 66 |
| Serum TARC, elevated | Negative | 63, 65 |
| Serum galectin-1, elevated | Negative | 64, 79 |
| Serum CD163, elevated | Negative | 65 |
| Serum IL-10, elevated | Negative | 73, 76, 78 |
| Serum IL-10 receptor, elevated | Negative | 76 |
| Serum IL-6, elevated | Negative | 76 |
| Serum CD30, elevated | Negative | 76, 78 |
| Serum TNF, elevated | Negative | 76 |
| Serum TNF receptor, elevated | Negative | 76 |
| Serum CD4, elevated | Negative | 78 |
| Serum CD8, elevated | Negative | 78 |
| Serum CD25, elevated | Negative | 78 |
| Serum CD54, elevated | Negative | 78 |
| Gene expression and miRNA profiling reflecting the tumor microenvironment | ||
| Gene expression profiling | Positive or negative | 62, 69 |
| Global miRNA levels, including MIR21, MIR30E, MIR30D, and MIR92B | Positive or negative | 80, 81 |
| Host germline polymorphisms and mutations | ||
| IL-10-specific polymorphism 592AA | Negative | 74 |
| IL-6-specific polymorphism 174GG | Negative | 74 |
| Germline NPAT mutation | Marker for risk of nodular lymphocyte–predominant Hodgkin lymphoma | 71 |
IL, interleukin; miRNA, microRNA; TARC, thymus and activation-regulated chemokine; TNF, tumor necrosis factor.
Presence detected by immunohistochemistry on tumor Hodgkin Reed-Sternberg cells.
Presence detected by immunohistochemistry on circulating peripheral blood CD30-positive cells.
Presence detected by immunohistochemistry on tumor microenvironment cells.